Product image of Zinplava (Bezlotoxumab) supplied by GNH India

Zinplava

Active Ingredient:
Bezlotoxumab
Origin:
EU

Zinplava (Bezlotoxumab)

Zinplava (bezlotoxumab) is an intravenous medication used to reduce recurrence of Clostridioides difficile infection in adults. It targets C. difficile toxins to support recovery. This overview covers key details for informed use. Short meta: Bezlotoxumab helps prevent recurrent C. difficile infection after antibiotic treatment.

Manufacturer / TM Owner

Merck Sharp & Dohme B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

  • Zinplava is prescribed to lower the risk of C. difficile infection returning in adults who have completed antibiotic therapy. It works by neutralizing toxins produced by the bacteria, supporting the body’s recovery process. This medication is used alongside standard treatments to help prevent recurrence. It is not a first-line therapy for active infections.

Side Effects

  • After infusion, bezlotoxumab circulates in the bloodstream to bind and neutralize C. difficile toxins. Patients may notice improved gastrointestinal comfort as the body stabilizes. The effects are supportive rather than curative, working to prevent symptom return. Individual responses vary based on health and infection history.

Precautions & Warnings

  • Zinplava is given by healthcare professionals in a controlled setting to monitor for reactions. Patients with a history of heart failure should inform their provider before use. Infusion-related reactions, though uncommon, may occur and require immediate attention. Always disclose full medical history to your healthcare team.

Avoid Interactions

  • Bezlotoxumab is a monoclonal antibody and generally does not interact with other medications. No specific drug interactions have been widely reported, but inform your doctor of all current medications. Combining with other C. difficile treatments may be part of a broader care plan. Alcohol use does not directly affect bezlotoxumab efficacy.

Frequently Asked Questions

Zinplava is used to reduce the recurrence of Clostridioides difficile infection in adults after antibiotic treatment.

Zinplava is given as an intravenous infusion by a healthcare professional in a clinical setting.

Consult your healthcare provider to assess risks and benefits if pregnant or breastfeeding.

Common effects may include nausea, headache, or infusion-related reactions like fever or chills.

Zinplava helps prevent recurrence but is not a standalone cure for active C. difficile infection.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated:

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Bezlotoxumab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT